HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PRPO
Precipio, Inc.
There isn't enough reported data to score PRPO yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PRPO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Strong |
PRPO's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PRPO PE Valuation
PRPO has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PRPO Forward outlook
There aren't enough analyst estimates for PRPO to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PRPO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.57 | +$0.24 |
| Q2 2026 | -$0.62 | +$0.56 |
| Q1 2026 | -$0.45 | +$1.61 |
| Q4 2025 | -$0.23 | +$2.70 |
| Q3 2025 | -$0.81 | +$1.24 |
| Q2 2025 | -$1.18 | +$1.49 |
| Q1 2025 | -$2.06 | +$1.58 |
| Q4 2024 | -$2.93 | +$1.85 |
PRPO has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PRPO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PRPO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.3M | +8.3% |
| Q2 2026 | $7M | +24% |
| Q1 2026 | $6.7M | +36% |
| Q4 2025 | $6.7M | +23% |
| Q3 2025 | $6.8M | +30% |
| Q2 2025 | $5.7M | +27% |
| Q1 2025 | $4.9M | +44% |
| Q4 2024 | $5.5M | +26% |
PRPO's revenue has grown year over year for 15 quarters in a row: $7M last quarter, up 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0% | +0.9 points |
| Q2 2026 | -8.5% | +6 points |
| Q1 2026 | -21% | -3.9 points |
| Q4 2025 | 8.1% | +14 points |
| Q3 2025 | -0.9% | +11 points |
| Q2 2025 | -15% | +13 points |
| Q1 2025 | -17% | +43 points |
| Q4 2024 | -6.2% | +14 points |
PRPO has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
PRPO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $554K | +$598K |
| Q2 2026 | $528K | +80% |
| Q1 2026 | $14K | +$196K |
| Q4 2025 | $291K | -44% |
| Q3 2025 | -$44K | +$24K |
| Q4 2024 | $521K | +702% |
| Q3 2024 | -$68K | +$851K |
| Q4 2023 | $65K | +$1.6M |
PRPO has burned cash in most quarters: $1M over the past year, up 135% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PRPO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PRPO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +3.5K shares |
| 1 year | +9.4% | +153K shares |
| 3 years | +28% | +396K shares |
| 5 years | +58% | +655K shares |
| Available history | +529% | +1.5M shares |
PRPO has 2M diluted shares, up 9.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PRPO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -59.9x | Net Cash |
PRPO has the edge over HIMS on leverage, with a lower net debt burden relative to earnings.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PRPO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.6 | Neutral |
| Stochastic | 14.4 | Oversold |
PRPO's weekly RSI is 50 (neutral) and its Stochastic is 14 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PRPO PE vs Healthcare Sector
PRPO has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PRPO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.4 | 8.6% above |
| 20 week MA | $23.9 | 2.8% below |
| 50 week MA | $24.6 | 5.3% below |
| 100 week MA | $18.2 | 27% above |
| 200 week MA | $13.1 | 78% above |
PRPO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PRPO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.8 | $41.8 | +2.5% |
| 2021 | $41.8 | $35.6 | -15% |
| 2022 | $35.6 | $11.0 | -69% |
| 2023 | $11.0 | $6.50 | -41% |
| 2024 | $6.50 | $5.51 | -15% |
| 2025 | $5.51 | $23.8 | +331% |
| 2026 YTD | $23.8 | $23.3 | -2.1% |
PRPO has the edge over HIMS on returns for 2026, with the stronger performance.